alexa Intranasal Insulin, Deferoxamine And Therapeutic Cells Bypass The Blood-brain Barrier To Treat Alzheimer?s And Other Brain Disorders
ISSN: 2161-0460

Journal of Alzheimers Disease & Parkinsonism
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

2nd International Conference on Alzheimers Disease and Dementia
September 23-25, 2014 Valencia Convention Centre, Spain

William H Frey II
Accepted Abstracts: J Alzheimers Dis Parkinsonism
DOI: 10.4172/2161-0460.S1.010
Abstract
Intranasal delivery provides a noninvasive method of bypassing the blood-brain barrier to deliver therapeutic agents to the brain within minutes. It also reduces unwanted side effects. This is possible because of the unique connections that the olfactory and trigeminal nerves provide between the brain and external environment. Using this delivery, targeting and treatment method which the author first invented in 1989, drugs and therapeutic proteins have been used to treat Alzheimer?s, Parkinson?s, stroke and other brain disorders in animal models. The intranasal insulin treatment for Alzheimer?s disease, which the author patented in 2001, has been shown to improve memory in normal human adults and improve memory, attention and functioning in patients with Alzheimer?s disease in multiple Phase 2 clinical trials without altering blood levels of insulin or glucose. Intranasal insulin may be able to reduce the risk of aging diabetics and others from developing Alzheimer?s disease. Iron accumulates in the brains of patients with Alzheimer?s and other neurodegenerative disorders. Intranasal deferoxamine binds iron, improves memory in normal mice and treats rodent models of Alzheimer?s, Parkinson?s and stroke. Together with Dr. Lusine Danielyan and colleagues in Germany, it was shown that intranasal therapeutic cells bypass the blood-brain barrier by migrating from the nasal mucosa along the olfactory neural pathway into the brain and spinal cord. Using intranasal therapeutic cells in animal models, the author demonstrated improvement in animal models of Alzheimer?s and Parkinson?s disease while others have reported improvement in neonatal ischemia, stroke and multiple sclerosis. Intranasal delivery is changing the way we treat brain disorders.
Biography
William H Frey II is Director of the Alzheimer?s Research Center of the Center for Memory and Aging at Regions Hospital in St. Paul, MN, Professor of Pharmaceutics and faculty member in Neurology and Neuroscience at the University of Minnesota and consultant to the pharmaceutical industry. His noninvasive intranasal method for bypassing the blood-brain barrier to target therapeutic agents to the brain while reducing systemic exposure and unwanted side effects has captured the interest of both pharmaceutical companies and scientists. The intranasal insulin treatment he developed for Alzheimer?s disease has been shown in clinical trials to improve memory in both Alzheimer?s patients and normal adults. His intranasal therapeutic cell delivery and treatment methods have been validated in animals for Parkinson?s, stroke, MS, brain tumors and other brain disorders. With over 100 publications in scientific and medical journals, he has been interviewed on Good Morning America, The Today Show, 20/20, All Things Considered. Articles about his research have appeared in the Wall Street Journal, The New York Times and other magazines and newspapers around the world. He earned his BA in Chemistry at Washington University in 1969 and PhD in Biochemistry at Case Western Reserve University in 1975.
image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords